Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

f-of-concept trial noted outlined above. With the positive initial results from that clinical trial and the decision to move forward to a Phase 2b outpatient clinical trial in migraine patients, Alexza must file a new IND with the DNP. It is projected that the Company will file this new IND in the fourth quarter of 2008 and initiate our Phase 2b outpatient study in the first quarter of 2009. AZ-104 has been licensed to Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-002 (Staccato alprazolam). Alexza is developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In June 2008, the Company announced the top line results of our in-clinic, single-center, double-blind, placebo-controlled, Phase 2a proof-of-concept clinical trial in patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a 1 mg single dose of AZ-002 in treating a pharmacologically-induced panic attack. Differences versus placebo in the intensity and the duration of a panic attack were collected at multiple time points during the study using psychological and physiological measurements. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population.

Thorough pharmacokinetic and pharmacodynamic analyses from this study show that alprazolam was administered in an IV-like manner with the Staccato system. Similar blood levels were observed in this study as were recorded during the AZ-002 Phase 1 PK and safety study in normal volunteers. Alexza and Symphony Allegro are completing work on the Phase 2a program for AZ-002 in acute panic attack. Following this com
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ill. , July 22, 2014  UL ... announced that the U.S. Food and Drug Administration ... as consensus standards for medical devices incorporating lithium ... 2054 - Standard for Household and Commercial Batteries, ... (Cells). Consensus standards are standards ...
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... SAN MARCOS, Texas , July 22, 2014 Quantum ... Martin and Mr. John Heaton to the Board ... chaired by Dr. Ghassan Jabbour , QMC Chief Science Officer ... Dr. Michael Wong of Rice University and Mr. ... Japan . " Quantum Materials ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Bowl champion coach, Fox NFL Sunday host and ... ExtenZe, the male enhancement brand, he has good-naturedly taken a ... national television. Now, in this next flight of ... fun, laughing about being put on the spot and made ...
... AMGN ) today announced that results from ... be presented at the 35th European Society for Medical ... "Cancer is a complex disease which ... pathways to develop novel therapies to treat cancer and ...
Cached Medicine Technology:Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 2Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 2Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 4Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 5Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 6Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 7Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 8Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 9Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 10Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 11Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 12Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 13Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 14Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 15Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 16
(Date:7/22/2014)... SIMpalm, a leading Mobile App Development ... Payment System. Forte Mobile Payment app allows merchants to ... and iPad. The app was originally launched in ... This update was for iOS 7.0 compatibility and iPhone ... and is available to download on the iPhone app ...
(Date:7/22/2014)... cholesterol treatment and cardiovascular risk assessment state that men ... atherosclerotic cardiovascular disease or of having a heart attack ... profile (based on age, smoking history, and cholesterol and ... when and how aggressively to treat high cholesterol are ... Health , a peer-reviewed publication from Mary Ann Liebert, ...
(Date:7/22/2014)... TX (PRWEB) July 22, 2014 The ... Program and third annual Institute Scholar Program. These offerings ... of the patient experience in healthcare and the need ... , The grant and scholar programs are ... , Value of focusing on the patient ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... park is the heart of a community. That’s ... made a recent investment in outdoor recreation and fun ... equipment from American Parks Company™. , The community of ... a 475-unit community that was established in the 1970s. ... tropical paradise with lush shade trees, green-edged walking and ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... with The Bakersfield based Comprehensive Blood and Cancer center (CBCC), ... an other six months the CBCC of US is to ... Kuruvilla the CEO of Apollo Hospital said that, "It will ... have within the hospital premises a separate unit that will ...
... A new ultra light hand, called the 'Southampton Remedi-Hand' has been ... hand better than any currently available. // ,The human hand ... movements and actions. The artificially developed hand is dependent on 6 ... way so as to enable independent movement of all the five ...
... that their neighborhoods are safe then their preschool children ... points out that this does not mean that these ... comparison with their counterparts in unsafe neighborhoods. ,Drawing ... researchers reported these findings in the September issue of ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... emergency room with cervical spinal injury may have more damage ... published in the Annals of Emergency Medicine, say that CT ... over and above the normal X-rays.// ,The study indicates ... additional spinal damage not visible on regular x-rays. In fact, ...
... announcement the Health Minister of West Bengal Mr.Surya Kanta Mishra ... and the numbers of cases detected were increasing in ... other than dengue, malaria, typhoid, viral fever and encephalitis were ... was also reported in N.Delhi last week in India. Dengue ...
Cached Medicine News:Health News:New ultralight hand with better functionality and flexibility developed 2Health News:Safe Neighborhood Means Less TV For Preschool Children 2Health News:Folic acid enriched grain reduces birth defects 2
BD Vacutainer® Fluoride Tubes - Glass...
BD Vacutainer® Specialty Tubes - Trace Element - Glass...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: